Cantor Research Laboratory
Blauvelt, New York, 10913, United States
NCT Number: NCT04253704
This was a placebo-controlled double-blinded trial to compare effects of 2% IDL lotion to placebo in female subjects with dry skin. Primary endpoints were skin hydration (NovaMeter) and transepidermal water loss (VapoMeter).
Looking for future studies?
Notify Me35 year–57 year
Female
Interventional
Phase 1 / Phase 2
Blauvelt, New York, 10913, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
IDL lotion is water-based (> 80%) with isosorbide di-(linoleate/oleate) (2.0%), caprylic/capric triglycerides (5%), glycerin (3%), glyceryl stearate (2.5%), dimethicone (2.0%), steareth-20 (1.5%), cetyl alcohol (1.0%), and butyrospermum parkii (shea) butter (1.0%).
Other names: IDL RC-02-38 / P0104-B1
Control lotion is water-based (> 80%) with caprylic/capric triglycerides (5%), glycerin (3%), glyceryl stearate (2.5%), dimethicone (2.0%), steareth-20 (1.5%), cetyl alcohol (1.0%), and butyrospermum parkii (shea) butter (1.0%).
Other names: RC-02-38A / P0104-B2
Time frame: Days 0, 7, 14 and 18
Change in skin hydration (NovaMeter assessment)
Time frame: Days 0, 14 and 18
Change in transepidermal water loss (Vapometer assessment)
Shyla Cantor
Industry
Placebo-controlled Double-blinded Trial to Evaluate the Effects of Short-term (1-2 Weeks) Treatment With 2% (Isosorbide di-(Linoleate/Oleate)) (IDL) Lotion on Skin Hydration and Transepidermal Water Loss in Females With Dry Skin
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07360639
Dry Skin, Xerosis Cutis
Banda Aceh, Nanggore Aceh Darussalam, Indonesia
View Trial DetailsNCT07162454
Cardiovascular Diseases, Diabetes Complications
Madrid, Spain
View Trial DetailsNCT07066150
Acne Vulgaris, Acneiform Eruptions
Qingdao, Shandong, China
View Trial DetailsNCT06178367
Xerosis Cutis
Jakarta, DKI Jakarta, Indonesia
View Trial Details